7
Participants
Start Date
June 20, 2016
Primary Completion Date
September 6, 2016
Study Completion Date
November 8, 2016
ATI-9242
"Formulated ATI-9242 will be administered as an IV bolus injection (2mg/mL of ATI-9242 in 40% solution of propylene glycol).~Two doses will be tested: single IV bolus injection of 0.5mg/kg and single IV bolus injection 1.0 mg/kg. In the event that a third cohort is needed the IV bolus injection would be 2.0 mg/kg"
[18F]Fallypride Imaging
Subjects will be injected with approximately 250 MBq or 6.75 mCi of \[18F\]Fallypride \[5-6 mCi being the typical range of injected dose\].
Indiana Clinical Research Center, IU Health University Hospital, Indianapolis
Lead Sponsor
Braeburn Pharmaceuticals
INDUSTRY